| Target Price | kr339.15 |
| Price | kr249.00 |
| Potential |
36.20%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Medistim 2027 .
The average Medistim target price is kr339.15.
This is
36.20%
register free of charge
kr357.00
43.37%
register free of charge
kr328.25
31.83%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Medistim to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medistim stock has an average upside potential 2027 of
36.20%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million kr | 699.77 | 816.00 |
| 24.38% | 16.61% | |
| EBITDA Margin | 31.58% | 31.12% |
| 14.21% | 1.47% | |
| Net Margin | 22.75% | 21.56% |
| 23.28% | 5.24% |
3 Analysts have issued a sales forecast Medistim 2026 . The average Medistim sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Medistim EBITDA forecast 2026. The average Medistim EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Medistim Analysts have issued a net profit forecast 2026. The average Medistim net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share kr | 8.71 | 9.62 |
| 53.62% | 10.45% | |
| P/E | 25.89 | |
| EV/Sales | 5.39 |
3 Analysts have issued a Medistim forecast for earnings per share. The average Medistim EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


